Physician profile
John B Wilson
NPI 1326047200
$5,602.65
in general payments reported to CMS, 2019-2025
51 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,556 · 2020: $860 · 2021: $1,481 · 2022: $30.72 · 2024: $406 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $491.35 | 2019-2025 | Nayzilam, Briviact |
| Amgen INC. | $458.34 | 2019-2021 | |
| Abbvie INC. | $427.93 | 2021-2025 | |
| Allergan, INC. | $341.13 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $274.39 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $268.23 | 2019-2021 | |
| Lilly USA, LLC | $259.18 | 2019-2024 | Kisunla, Amyvid |
| Acadia Pharmaceuticals INC | $256.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $226.62 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $216.57 | 2019-2021 | |
| Acorda Therapeutics, INC | $206.44 | 2019-2020 | |
| Mdd US Operations, LLC | $185.90 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $162.86 | 2021-2024 | Ingrezza |
| Biogen, INC. | $111.99 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.